Relyea Zuckerberg Hanson LLC Buys 3,522 Shares of AbbVie Inc. $ABBV

Relyea Zuckerberg Hanson LLC grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 14.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,168 shares of the company’s stock after acquiring an additional 3,522 shares during the period. Relyea Zuckerberg Hanson LLC’s holdings in AbbVie were worth $6,436,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of AbbVie by 0.3% during the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock worth $41,155,601,000 after purchasing an additional 448,554 shares during the period. Legal & General Group Plc boosted its stake in AbbVie by 4.3% in the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after purchasing an additional 493,420 shares during the period. Wellington Management Group LLP boosted its stake in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Amundi grew its holdings in AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after buying an additional 1,414,621 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in AbbVie by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock valued at $2,241,363,000 after buying an additional 408,426 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 0.0%

Shares of AbbVie stock opened at $208.79 on Friday. The firm’s 50 day moving average is $221.58 and its 200 day moving average is $224.41. The firm has a market capitalization of $369.17 billion, a PE ratio of 88.47, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is 293.22%.

Insider Buying and Selling at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ABBV. UBS Group dropped their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Royal Bank Of Canada initiated coverage on shares of AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target on the stock. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.